Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any neonatal inflammatory skin and bowel disease in which the cause of the disease is a mutation in the EGFR gene.
Features include always present findings: Polyhydramnios, Increased circulating IgE concentration, Pustule, and Coarctation of aorta and others. 14 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 2 | Vomiting, Secretory diarrhea |
EGFR encodes epidermal growth factor receptor (1,210 aa). Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Highest expression in Skin Sun Exposed Lower leg (78.3 TPM) and Skin Not Sun Exposed Suprapubic (75.9 TPM).
Inflammatory skin and bowel disease, neonatal, 2 is associated with mutations in the EGFR gene on chromosome 7.
The EGFR protein participates in EGFR E746_S752delinsV, EGFR L747_A750delinsP, and EGFR D770_N771insNPG pathways.
EGFR is classified as a druggable target (Cell Surface, Clinically Actionable, Drug Resistance, Druggable Genome, Kinase, and Tyrosine Kinase categories) with score 1.4.
Genetic testing for EGFR is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for inflammatory skin and bowel disease, neonatal, 2 has been reported in the published literature.
Phenotype severity distribution: 10 always present features.
No clinical trials have been registered for inflammatory skin and bowel disease, neonatal, 2.
4 publications have been identified in PubMed for inflammatory skin and bowel disease, neonatal, 2. Research spans Case Report / Case Series (50%), Diagnostic / Biomarker (25%), and Epidemiology / Natural History (25%).
Chang HR (2026). [PMID: 40968583](https://pubmed.ncbi.nlm.nih.gov/40968583/). *Pediatr Dermatol*. [Case Report / Case Series]
Karabinos A (2025). [PMID: 40040597](https://pubmed.ncbi.nlm.nih.gov/40040597/). *J Dermatol*. [Case Report / Case Series]
Negera A (2025). [PMID: 39910213](https://pubmed.ncbi.nlm.nih.gov/39910213/). *Sci Rep*. [Epidemiology / Natural History]
Niehues T (2024). [PMID: 39381601](https://pubmed.ncbi.nlm.nih.gov/39381601/). *Allergol Select*. [Diagnostic / Biomarker]
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 1:46 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
2 |
Recurrent bronchiolitis, Recurrent pneumonia |
Lab test results | 1 | Increased circulating IgE concentration |
Growth and development | 1 | Failure to thrive |
Heart and blood vessels | 1 | Hypertension |
Skin | 1 | Papule |